Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 133,76 € (-33,32%). La mediana è 122,46 € (-38,95%).
| Acquista |
7 |
| Mantieni |
16 |
| Vendi |
6 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Moderna beats Q3 expectations and raises full-year guidance
Moderna reported third-quarter revenue up 29% to $1.3 billion and net income of $162 million, far above the expected $885 million in revenue and an anticipated loss. The company raised its revenue forecast for the fiscal year to a gain of 15–25% and updated its year‑end cash expectation to $8.1–8.3 billion. The strong results pushed the stock sharply higher in premarket trading. » Altro su deraktionaer.de
Moderna posts over 650% year-to-date gain in 2026, ahead of Micron and Nvidia
Moderna shares have risen more than 650% year-to-date, significantly outperforming names like Micron and Nvidia. Drivers include mRNA technology, successful COVID-19 revenues and a diversified pipeline with respiratory vaccines, oncology programs and treatments for rare diseases. Attention is focused on Intismeran autolog and a phase‑3 combination with Keytruda in melanoma; on November 6 Moderna will release quarterly results and has confirmed revenue growth of up to 10% for the year. Investors are expecting further details on the flu vaccine and the oncology opportunities. » Altro su deraktionaer.de
Moderna delivers 197.82% return for investors since October 2023
An investment of $10,000 in Moderna on October 29, 2023 (closing price $71.91) would have grown to $29,782.37 by October 28, 2026 at a share price of $214.17. That corresponds to an increase of the original investment by 197.82%. Moderna was most recently valued at $85.63 billion; stock splits and dividends were not taken into account in the calculation. » Altro su finanzen.net
AstraZeneca to enter cancer vaccines and go head-to-head with Moderna and Merck
AstraZeneca announces plans to push into the cancer-vaccine business, driven by the success of personalized mRNA therapies from Moderna and Merck. CEO Pascal Soriot points to years of mRNA research, while oncology chief Dave Fredrickson concedes that competitors are currently further ahead. AstraZeneca is focusing on areas with high quality, pioneering roles and scale effects; the infectious-disease division will concentrate on non-personalized vaccines. The stock has recovered after consolidation, with the 200-day moving average at just under 13,500 pence an important technical hurdle; dividend yield around 2.0%, quarterly report on October 30. » Altro su deraktionaer.de
Moderna shares fall after analyst downgrade and cautious data on Intismeran
Moderna shares drop about eight percent, extending a correction after preliminary Intismeran data leaked. William Blair removed its buy rating and downgraded to "Market Perform", saying the success of the personalized melanoma vaccine still needs to be demonstrated in other tumor types. Analysts see potential for a new treatment standard but warn of substantial clinical and biological risks in expanding to kidney, bladder and lung cancer. » Altro su deraktionaer.de
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 1,16 Mld | 33,89% |
| Utile lordo | 878,44 Mln | 12.785,89% |
| Utile netto | 143,02 Mln | 183,92% |
| EBITDA | 211 Mln | 283,42% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 81,99 Mld € |
Numero di azioni | 404,62 Mln |
Massimo/minimo a 52 settimane | 254,73 € - 20,21 € |
| Dividendi | No |
Beta | 0,90 |
Rapporto P/E | -31,59 |
Rapporto PEG | -3,20 |
Rapporto P/B | 13,10 |
Rapporto P/S | 35,79 |
Profilo aziendale
Moderna, Inc., una società di biotecnologie, scopre, sviluppa e commercializza terapie e vaccini basati sull'RNA messaggero per il trattamento delle malattie infettive, dell'immuno-oncologia, delle malattie rare, delle malattie cardiovascolari e delle malattie autoimmuni negli Stati Uniti, in Europa e a livello internazionale. I suoi vaccini respiratori includono quelli contro COVID-19, influenza, virus respiratorio sinciziale, HCoV endemici e hMPV+PIV3; i vaccini latenti comprendono quelli contro citomegalovirus, virus di Epstein-Barr, virus dell'immunodeficienza umana, virus herpes simplex e virus varicella-zoster; i vaccini di sanità pubblica comprendono quelli contro Zika e Nipah. La società offre inoltre terapie sistemiche secrete e di superficie cellulare; vaccini oncologici, come quelli personalizzati contro il cancro, KRAS e checkpoint; prodotti intratumorali di immuno-oncologia; terapie rigenerative localizzate, terapie intracellulari sistemiche e terapie polmonari per inalazione. Ha alleanze strategiche con AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; la Defense Advanced Research Projects Agency; la Biomedical Advanced Research and Development Authority; l'Institute for Life Changing Medicines; e la Bill & Melinda Gates Foundation, nonché un accordo di collaborazione e licenza con Chiesi Farmaceutici S.P.A. La società era precedentemente nota come Moderna Therapeutics, Inc. e ha cambiato nome in Moderna, Inc. nell'agosto 2018. Moderna, Inc. è stata fondata nel 2010 e ha sede a Cambridge, Massachusetts.
| Nome | Moderna Inc. |
| CEO | Stéphane Bancel |
| Sede centrale | Cambridge,
ma Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 07/12/2018 |
| Dipendenti | 4700 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | MRNA |
XETRA | 0QF.F |
Frankfurt | 0QF.F |
Düsseldorf | 0QF.DU |
Hamburg | 0QF.HM |
Milan | 1MRNA.MI |
London | 0A45.L |
SIX | 0QF.SW |
München | 0QF.MU |
Wien | MRNA.VI |